NDI Medical

NDI relies on proprietary platform technologies — implantable pulse generators, leads, and surgical tools — that it adapts to multiple therapeutic applications. It sources invention opportunities through formal partnerships with the Cleveland FES Center, Case Western Reserve University, Cleveland Clinic, MetroHealth Medical Center, and Duke University. The firm’s research and development teams work directly with clinician end-users to shape products toward unmet clinical needs.

NDI describes itself as a hybrid venture capital and commercialization firm. It deploys capital through the NDI Healthcare Fund, but unlike a traditional fund manager it builds companies on top of its own shared IP and engineering platform. This means the firm takes an active role in product development, regulatory work, and commercial launch — not just board-level oversight.

NDI invests exclusively in neurodevice technologies — stimulators, leads, surgical equipment, and associated software — targeting conditions such as chronic pain, Parkinson’s disease, depression, epilepsy, obesity, and stroke. It does not invest in pharmaceuticals, biologics, or non-device healthcare services. The firm’s stated focus is entirely on neuromodulation and neurostimulation.